Unopposed estrogen therapy and the risk of invasive breast cancer
- PMID: 16682578
- DOI: 10.1001/archinte.166.9.1027
Unopposed estrogen therapy and the risk of invasive breast cancer
Abstract
Background: Although short-term unopposed estrogen use does not seem to increase breast cancer risk, the effect of longer-term estrogen use remains unclear. We sought to assess the relationship between longer-term use of unopposed estrogen and the risk of invasive breast cancer over an extended follow-up period.
Methods: Within the Nurses' Health Study, a prospective cohort study, we observed 11 508 postmenopausal women who had a hysterectomy and reported information on estrogen use at baseline (1980). The study population was expanded every 2 years to include women who subsequently became postmenopausal and had a hysterectomy, so that 28 835 women were included in the final follow-up period (2000-2002). Estrogen use was assessed from self-reported data on biennial questionnaires. The main outcome was invasive breast cancer.
Results: A total of 934 invasive breast cancers were included in the analysis. Breast cancer risk increased with duration of unopposed estrogen use among longer-term users with the highest risk seen in cancers positive for estrogen receptor (ER+) and progesterone receptor (PR+). The multivariate relative risks (RRs) and 95% confidence intervals (CIs) for breast cancer with current use of unopposed estrogen for less than 5 years, 5 to 9.9 years, 10 to 14.9 years, 15 to 19.9 years, and 20 years or longer were, respectively, 0.96 (95% CI, 0.75-1.22), 0.90 (95% CI, 0.73-1.12), 1.06 (95% CI, 0.87-1.30), 1.18 (95% CI, 0.95-1.48), and 1.42 (95% CI, 1.13-1.77) (P for trend <.001 the risk of er breast cancers was noted to be statistically significant after years current use ci>
Conclusion: Users of unopposed estrogen were at increased risk of breast cancer but only after longer-term use.
Similar articles
-
Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones.J Natl Cancer Inst. 2005 Apr 20;97(8):595-602. doi: 10.1093/jnci/dji099. J Natl Cancer Inst. 2005. PMID: 15840882
-
Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer.J Clin Oncol. 2008 Mar 10;26(8):1260-8. doi: 10.1200/JCO.2007.13.4338. J Clin Oncol. 2008. PMID: 18323549 Free PMC article.
-
Predicting risk of breast cancer in postmenopausal women by hormone receptor status.J Natl Cancer Inst. 2007 Nov 21;99(22):1695-705. doi: 10.1093/jnci/djm224. Epub 2007 Nov 13. J Natl Cancer Inst. 2007. PMID: 18000216 Clinical Trial.
-
Breast cancer risk with postmenopausal hormonal treatment.Hum Reprod Update. 2005 Nov-Dec;11(6):545-60. doi: 10.1093/humupd/dmi028. Epub 2005 Sep 8. Hum Reprod Update. 2005. PMID: 16150813 Review.
-
Adult weight gain in relation to breast cancer risk by estrogen and progesterone receptor status: a meta-analysis.Breast Cancer Res Treat. 2010 Oct;123(3):641-9. doi: 10.1007/s10549-010-1116-4. Epub 2010 Aug 15. Breast Cancer Res Treat. 2010. PMID: 20711809 Review.
Cited by 44 articles
-
Expression of PGRMC1 in paraffin-embedded tissues of breast cancer.Int J Clin Exp Pathol. 2017 Sep 1;10(9):9639-9643. eCollection 2017. Int J Clin Exp Pathol. 2017. PMID: 31966843 Free PMC article.
-
Breast Cancer Risk in Postmenopausal Women with Medical History of Thyroid Disorder in the Women's Health Initiative.Thyroid. 2020 Apr;30(4):519-530. doi: 10.1089/thy.2019.0426. Epub 2020 Feb 3. Thyroid. 2020. PMID: 31918623
-
Update on Menopausal Hormone Therapy for Fracture Prevention.Curr Osteoporos Rep. 2019 Dec;17(6):465-473. doi: 10.1007/s11914-019-00549-3. Curr Osteoporos Rep. 2019. PMID: 31741221 Free PMC article. Review.
-
Lasting impact on memory of midlife exposure to exogenous and endogenous estrogens.Behav Neurosci. 2018 Dec;132(6):547-551. doi: 10.1037/bne0000270. Epub 2018 Aug 30. Behav Neurosci. 2018. PMID: 30160505 Free PMC article.
-
Previous estradiol treatment in ovariectomized mice provides lasting enhancement of memory and brain estrogen receptor activity.Horm Behav. 2018 Jun;102:76-84. doi: 10.1016/j.yhbeh.2018.05.002. Epub 2018 May 12. Horm Behav. 2018. PMID: 29742445 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
Grant support
LinkOut - more resources
-
Full Text Sources
-
Other Literature Sources
-
Medical
-
Research Materials